Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies
Open Access
- 2 April 2020
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 477 (7), 1203-1218
- https://doi.org/10.1042/bcj20190843
Abstract
Mutations in the Parkinson's disease (PD)-associated protein leucine-rich repeat kinase 2 (LRRK2) commonly lead to a reduction of GTPase activity and increase in kinase activity. Therefore, strategies for drug development have mainly been focusing on the design of LRRK2 kinase inhibitors. We recently showed that the central RocCOR domains (Roc: Ras of complex proteins; COR: C-terminal of Roc) of a bacterial LRRK2 homolog cycle between a dimeric and monomeric form concomitant with GTP binding and hydrolysis. PD-associated mutations can slow down GTP hydrolysis by stabilizing the protein in its dimeric form. Here, we report the identification of two Nanobodies (NbRoco1 and NbRoco2) that bind the bacterial Roco protein (CtRoco) in a conformation-specific way, with a preference for the GTP-bound state. NbRoco1 considerably increases the GTP turnover rate of CtRoco and reverts the decrease in GTPase activity caused by a PD-analogous mutation. We show that NbRoco1 exerts its effect by allosterically interfering with the CtRoco dimer–monomer cycle through the destabilization of the dimeric form. Hence, we provide the first proof of principle that allosteric modulation of the RocCOR dimer–monomer cycle can alter its GTPase activity, which might present a potential novel strategy to overcome the effect of LRRK2 PD mutations.This publication has 67 references indexed in Scilit:
- Number and Brightness Analysis of LRRK2 Oligomerization in Live CellsBiophysical Journal, 2012
- Nanobody stabilization of G protein-coupled receptor conformational statesCurrent Opinion in Structural Biology, 2011
- Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2Nature Chemical Biology, 2011
- Insight into the mode of action of the LRRK2 Y1699C pathogenic mutantJournal of Neurochemistry, 2010
- Membrane Localization of LRRK2 Is Associated with Increased Formation of the Highly Active LRRK2 Dimer and Changes in Its PhosphorylationBiochemistry, 2010
- Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on DimerizationOnline Journal of Public Health Informatics, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- Structure of the Roc–COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinaseThe EMBO Journal, 2008
- The Parkinson’s disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase thatstimulates kinase activityExperimental Cell Research, 2007
- The R1441C mutation of LRRK2 disrupts GTP hydrolysisBiochemical and Biophysical Research Communications, 2007